Clinical Trials Logo
  1. Home
  2. Carcinoid Syndrome
  3. NCT02063659

Telotristat Etiprate for Carcinoid Syndrome Therapy — TELECAST  

Carcinoid Syndrome Clinical Trial

Official title:
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome

Clinical Trial Summary

The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA) levels.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02063659
Study type Interventional
Source Lexicon Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date March 11, 2014
Completion date March 29, 2016
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04993261 - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors Early Phase 1
Not yet recruiting NCT04039516 - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy Phase 2
Completed NCT01234168 - A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Terminated NCT04073017 - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency N/A
Recruiting NCT05756608 - Fibrosis in Chronic and Delayed Myocardial Infarction
Completed NCT00774930 - An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome Phase 3
Withdrawn NCT04713202 - Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl Phase 2
Completed NCT00853047 - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy Phase 2
Withdrawn NCT04776876 - Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome Phase 2
Completed NCT03223428 - Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Recruiting NCT03453489 - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm Phase 2
Active, not recruiting NCT05361668 - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome Phase 2
Completed NCT01104415 - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Phase 2
Withdrawn NCT01172717 - Study of Panitumumab in the Treatment of Carcinoid Syndrome Phase 2
Terminated NCT00884715 - Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome Phase 1/Phase 2
Completed NCT01677910 - TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) Phase 3
Completed NCT01430871 - Effects of Serotonin Excess on Bone in Carcinoid Syndrome N/A
Completed NCT02026063 - Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms Phase 3
Terminated NCT01018953 - Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome Phase 2
Terminated NCT04140409 - Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation Phase 4